Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?

Autor:	M Dupont, Claire Carlier, C Gower-Rousseau, P Barbier-Lider, D Botsen, M Brasseur, A Burgevin, C Chourbagi, R D’Almeida, V Hautefeuille, M Hentzien, A Lambert, M Lamuraglia, S Lavau-Denes, A Lopez, D Parent, F Slimano, M Brugel, O Bouché
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	Cetuximab Infusion reaction Lyme disease Hypersensitivity Risk factors Alpha-gal Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Druh dokumentu:	article
ISSN:	1471-2407
DOI:	10.1186/s12885-022-10192-4
Popis:	Highlights In a large series of 1392 patients, the 266 patients treated in the French area with the highest incidence of Lyme disease were at a higher risk of cetuximab-induced hypersensitivity infusion reactions compared to those from other areas (16.4% versus 6.7%, 7.1% and 7.0% in medium-, low- and very-low-risk areas; P = 0.0015). The risk of cetuximab-induced hypersensitivity infusion reactions in head and neck squamous cell carcinoma patients was higher only in the area with the highest incidence of Lyme disease. Age, sex, premedication, primary cancer location and chemotherapy regimen type had no impact on the incidence of cetuximab-induced infusion reactions in the overall population.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/178b4307001c43c1b8483f8db31b2dd7 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.